Source: Optics Valley of China

On May 16, a leading company in China's medical device industry ——Mindray Hosts 2026 Core Supply Partners Conference in Optics Valley, bringing together over 200 core suppliers, authoritative experts, and industry representatives to discuss the frontiers of medical technology and global industrial collaboration, and jointly build new competitive advantages for the globalization of medical devices.

Mindray is one of the world's leading and China's largest medical device research, development, and manufacturing enterprises. Its product portfolio covers three major fields: life information and support, in vitro diagnostics, and medical imaging. The products are exported to more than 190 countries and regions worldwide, reaching 87 of the top 100 hospitals globally. The company boasts the most comprehensive product line in the industry, with nine product categories holding the No. 1 market share in China and six product categories ranking among the top three globally.

This conference is the highest-level and most globally influential industrial cooperation event of the year for Mindray.At the conference, several honors were awarded, including "Gold Supplier," "Global Outstanding Partner," "Joint Innovation Award," and "Best Delivery Award," in recognition of the outstanding contributions of global supply chain partners.

At the meeting, Mindray announced its global development strategy, global supply chain development plan, and global procurement management strategy, clarifying the strategic direction for the next phase:Driven by the three core pillars of globalization, streamlined business expansion, and digital intelligence, accelerate the comprehensive upgrade from a medical device supplier to a strategic partner empowering global healthcare systems.

As a "chain leader" enterprise in Wuhan's life and health industry, Mindray continues to deepen its presence in the city and increase investment: The Mindray Medical Wuhan Base, Mindray’s global second headquarters with a total investment of 4.5 billion yuan, has officially opened. Covering the entire chain of R&D, manufacturing, training, and other key links, it accelerates Wuhan’s development into a biopharmaceutical and medical device industrial cluster. Its subsidiary, Wuhan Mindray Scientific Co., Ltd., as a national-level high-tech enterprise,Specializing in orthopedics, minimally invasive surgery, and minimally invasive interventional proceduresThe research and production of high-value medical consumables make it a leading comprehensive enterprise in high-value medical consumables in central China.

A relevant official from Mindray stated that, with its global second headquarters in Wuhan as the core pivot, the company will accelerate R&D efforts on high-end medical equipment such as surgical robots and cardiovascular interventions. Meanwhile, the company is also focusing on advancing embodied intelligence and other digital and intelligent capabilities, driving medical devices to evolve from "intelligent perception" towards "intelligent action."

The Optics Valley Biolake, where Mindray's Wuhan base is located, has attracted over 4,200 well-known enterprises such as Pfizer, Sinopharm, United Imaging, and Mindray. It accounts for over 90% of the province's approved clinical Class I new drugs and over 70% of Class III medical device registration certificates in the province. Additionally, 16 products have entered the special review channel for innovative medical devices in China, establishing a leading life health industry ecosystem in the country.The comprehensive competitiveness ranks among the top echelon of biotechnology industrial parks in China.